eMed Transforms Women's Health

eMed's clinical model is now published in Nature Medicine, a top-tier medical research journal.
The study, led by University College London (UCL), followed over 8,000 women on the eMed program and is one of the largest real-world GLP-1 datasets.

“This study provides some of the most comprehensive real-world evidence to date on GLP-1 treatment in women. What's particularly striking is the consistency of outcomes across a large and diverse population.”

Professor John Deanfield
Institute of Cardiovascular Science, University College London

The Results Speak For Themselves

We proved the power of the eMed program - at scale

Weight-loss milestone at 6 months

(% of participants reaching each threshold)

  • Lost weight99.3%
  • Lost at least 5%96.1%
  • Lost at least 10%83.1%

A closer look at the women in the study

Ages
18-79

Diverse socioeconomic backgrounds including both pre / post menopausal women

38.2 BMI

Avg baseline, Obesity class II

8,127

Women treated by eMed clinicians

0

Serious Treatment Related side effects

Outcomes Built to Last

The Nature Study tracked results over 6 months, with over 91% of the members staying on the treatment.

-35
lbs

Average Weight Loss at 6 Months

15.5% average weight reduction achieved at 6 months of treatment.

91.4
%

Still on Treatment at 6 Months

15.5% average weight reduction achieved at 6 months of treatment.

93.6
%

Normalized Prediabetes (HbA1c)

Significant clinical reversal of prediabetes marker among participants with paired lab data.

Cardiovascular risk

Lipid Marker Reductions

Significant clinical improvements across all 3 markers.

Total cholesterol

-13%

5.71 → 4.94 mmol/L

5.71 mmol/L4.94 mmol/L

LDL cholesterol

-16%

3.77 → 3.16 mmol/L

3.77 mmol/L3.16 mmol/L

Triglycerides

-29%

1.64 → 1.17 mmol/L

1.64 mmol/L1.17 mmol/L

Key takeaways

Outcomes measured from day one, across every client population.

1
Peer-reviewed and independently analyzed.
Published in Nature Medicine. The study was led and analyzed independently by University College London.
2
Vast majority of participants stayed on the treatment.
91.4% were still on treatment at six months. Discontinuation was lower among those using structured side-effect support (5.0% vs 7.4%).
3
Results were achieved below the maximum dose.
Average dose exposure across the study sat at around 63% of the maximum licensed dose, and weight loss over six months was comparable to the trajectories reported in the major clinical trials of these treatments.
4
Blood sugar and cholesterol improved alongside weight.
84.5% of those in the diabetes range and 96.3% of those with prediabetes returned to normal blood sugar. Average total cholesterol moved into the healthy range.
5
Outcomes were consistent across the population.
No significant difference in weight loss by deprivation level, and results held at every age from 18 to 79. There were no serious treatment-related adverse events.

Contact our team